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Bone morphogenetic protein-7 (BMP-7) is a potential
therapeutic agent for acute and chronic renal diseases.
Here we found that addition of polymeric IgA, isolated
from patients with IgA nephropathy, increased the synthesis
of tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6),
transforming growth factor-b (TGF-b) and fibronectin in
cultured human mesangial cells, effects blunted by BMP-7.
When mesangial cells were cultured with both polymeric IgA
and BMP-7 there was an increase in the expression of
peroxisome proliferator-activated receptor-c (PPAR-c). The
activation of NFjB and TNF-a synthesis induced by polymeric
IgA or TNF-a were downregulated by BMP-7 or rosiglitazone.
BMP-7 inhibited TNF-a release from polymeric IgA-stimulated
mesangial cells by activation of PPAR-c but suppressed
TGF-b release by mechanisms independent of PPAR-c. The
expression of inhibitory Smad6 and 7 was increased whereas
the expression of active Smad2 and 3 was reduced in these
mesangial cells by BMP-7. Our study shows that BMP-7
ameliorates IgA nephropathy-derived polymeric IgA-induced
TNF-a and TGF-b synthesis in human mesangial cells through
multiple mechanisms involving inhibitory Smads and PPAR-c.
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IgA nephropathy (IgAN) is the most common chronic
glomerulonephritis worldwide.1 A prominent pathological
feature of the disease is the deposition of polymeric IgA
(pIgA) in the mesangium, followed by proliferation of the
mesangial cells and/or mesangial matrix.2 Polymeric IgA
from patient with IgAN causes glomerular damage by
inducing release of proinflammatory and profibrotic cyto-
kines, including tumor necrosis factor-a (TNF-a), inter-
leukin-6 (IL-6), and transforming growth factor-b (TGF-b),
in mesangial cells.3,4
Bone morphogenetic protein-7 (BMP-7), a member of the
TGF-b superfamily, is crucial in nephrogenesis during
development.5 BMPs exert their effects via two sets of
serine–threonine kinase receptors: a type-II receptor, which
binds ligand and a type-I receptor, which is recruited to the
complex and transduces the signal.6 BMP receptors (BMPRs)
identified to date include type-I receptors, activin receptor-like
kinase-2 (ALK2), BMPR-IA (or ALK3), BMPR-IB (or ALK6),
and type-II receptors, BMPR-II, activin receptor-II (ActRII)
and activin receptor-IIB (ActRIIB). Complex formation
between BMP-7 or TGF-b1 with type-II and ALK type-I
receptors leads to the intracellular signaling pathway mediated
by Smad proteins.7 Smad1, Smad5, and Smad8 transduce the
action of BMP-7, whereas Smad2 and Smad3 mediate the
action of TGF-b1 in epithelial cells. Smad4 is common to both
pathways. Membrane-bound, highly specific BMP-7 receptors
have been recently localized in the glomerulus, convoluted
tubules, and collecting tubules of the rat kidney, suggesting the
autocrine and paracrine role for BMP-7. BMP-7 has potential
as a therapeutic agent for treatment of acute and chronic renal
failure. Recent studies reveal BMP-7 can reduce the severity of
glomerulonephritis and tubulointerstitial fibrosis in various
experimental models of acute or chronic renal injury,
including unilateral ureteral obstruction,8 acute ischemic renal
injury,9 diabetic nephropathy,10 and lupus nephritis.11 BMP-7
exerts its antifibrotic effect in the kidney through counter-
acting the profibrotic effects of TGF-b in human mesangial
cells (HMCs)12 and proximal tubular epithelial cells.13 BMP-7
represses basal and TNF-a-induced expression of proinflam-
matory cytokines (IL-6 and IL-1b) and chemokines in
proximal tubular epithelial cells.13
Previously, we demonstrated that pIgA from patients with
IgAN is capable of inducing macrophage migration-inhibi-
tory factor and TNF-a production in HMCs.4 The finding
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2008 International Society of Nephrology
Received 6 December 2007; revised 18 February 2008; accepted 11
March 2008; published online 21 May 2008
Correspondence: Kar Neng Lai, Department of Medicine, University of Hong
Kong, Room 409, Professorial Block, Queen Mary Hospital, 102 Pokfulam
Road, Pokfulam, HKG, Hong Kong. E-mail: knlai@hkucc.hku.hk
1026 Kidney International (2008) 74, 1026–1039
that the neutralizing antibody to TNF-a partially blocked this
mesangial synthesis of macrophage migration-inhibitory
factor suggests the possibility of upregulatory macrophage
migration-inhibitory factor synthesis in HMCs being
mediated via an amplifying proinflammatory loop involving
TNF-a. pIgA1 in IgAN also upregulates the intrarenal
rennin–angiotensin system and TGF-b, leading to chronic
renal failure with renal fibrosis.3 Based on the counteracting
effect of BMP-7 on biological actions of TGF-b and TNF-a, it
is logical to hypothesize that BMP-7 could also counteract the
action of these profibrotic and proinflammatory cytokines in
IgAN and ameliorate the pIgA-induced renal injury. Despite
increasing evidence of the reno-protective role of BMP-7, its
role in IgAN has yet been explored. In this study, we
hypothesized that BMP-7 counteracts the action of these
profibrotic and proinflammatory cytokines in IgAN, and
hence reduces the pIgA-induced renal injury. We determined
the effect of BMP-7 on the action of TNF-a, IL-6, and TGF-b
in pIgA-stimulated HMCs, and analyzed the involved signal
transduction pathways.
RESULTS
Glomerular expression of BMP-7
Immunoreactive BMP-7 was found in podocytes in glomeruli
from normal subjects, but was weakly detectable in glomeruli
from IgAN patients (Figure 1). Localization of BMP-7 in
epithelial cells was demonstrated by double staining with
nephrin (Figure 1g and i). Glomerular BMP-7 score was
significantly lower in patients with IgAN (mean score 0.4667
versus 2.125 in control subjects, P¼ 0.0003) (Figure 1k).
Expression of receptors for BMP-7 in HMCs
Constitutive gene expression of the five BMP receptors,
including ALK2, ALK3, ALK6, ActRII, and BMPR-II, was
documented in cultured HMCs (Figure 2a). The protein
expression of these receptors was further confirmed by
immunohistochemical staining (Figure 2b). Compared with
pIgA isolated from healthy subjects, pIgA from patients with
IgAN had significantly decreased receptor expression of
ALK2, ALK6, and BMPR-II (Po0.01) when cultured with
HMCs (Figure 2c).
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Figure 1 | Detection of BMP-7 in human glomeruli. Representative hematoxylin and eosin staining (a, d), immunofluorescence staining
of nephrin (red; b, e), or BMP-7 (green; c, f) in glomeruli from normal subjects (a–c, g) and IgAN patients (d–f, i) (original magnification
 400). Overlay of nephrin and BMP-7 staining is shown in panels g and i. Cell nuclei were counterstained with 40,60-diamidino-2-
phenylindole hydrochloride (blue). Immunoreactive BMP-7 is found in the podocytes in the glomerulus from normal subject (c) and
is weakly expressed in glomeruli from IgAN patient (f). Colocalization of nephrin and BMP-7 staining in podocytes is indicated by
white arrowhead in the insets of panels g and i (h, j). (k) Semi-quantification of glomerular BMP-7 staining using a five-point scale.
Patients with IgAN are denoted by closed circles and control subjects are denoted by open circles. The glomerular BMP-7 score is
significantly lower in patients with IgAN.
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Effect of BMP-7 on cell proliferation and synthesis of
TNF-a, IL-6, and TGF-b induced by pIgA in HMCs
We then performed in vitro studies to determine whether
BMP-7 may exert any reno-protective effect in IgAN. Figure 3
depicts the metabolic activity and cell viability of HMCs
following incubation with pIgA preparations in the presence
or absence of BMP-7 for 48 h. Polymeric IgA from patients
with IgAN significantly increased the metabolic activity in
HMCs (Po0.05) when compared with pIgA from healthy
subjects (Figure 3a). Proliferation of HMCs induced by pIgA
was significantly reduced by BMP-7 (Po0.05). HMCs
remained viable when exposed to various IgA preparations
at a concentration of 0.5 mg/ml with or without BMP-7
(Figure 3b). Similar findings were obtained for HMC
proliferation as determined by bromodeoxyuridine incor-
poration assay (Figure 3c) and direct cell counting (Figure
3e). The increased cell proliferation was blunted by
preincubating HMCs with BMP-7 (Po0.001). There was
no increase in apoptosis in HMCs exposed to pIgA in the
presence or absence of BMP-7, as shown by the caspase-3
activity (Figure 3d) or TdT-mediated X-dUTP nick-end
labeling assay (Figure 3f). The concentration of BMP-7 used
in this study (up to 1000 ng/ml) neither induced apoptosis
nor affected the cell viability, metabolic activity, and HMC
proliferation (data not shown).
As depicted in Figures 4–7, gene expression and protein
release of TNF-a, IL-6, TGF-b, and fibronectin were
significantly increased in HMCs cultured with pIgA from
patients with IgAN when compared with pIgA from healthy
subjects at equivalent concentration of 0.5 mg/ml (Po0.001).
These upregulations were reduced when HMCs were
preincubated with BMP-7 (Po0.01). BMP-7 at concentra-
tions greater than 125 ng/ml reduced protein release of
TNF-a, IL-6, and TGF-b in a dose-dependent manner.
Recombinant TNF-a at a concentration 40.1 ng/ml
significantly increased TNF-a (Figure 8a) and IL-6 (Figure
8b) production by HMCs (Po0.001), but the upregulation
was blocked by BMP-7 at a concentration of 250 ng/ml
(Po0.01). However, TNF-a exerted no effect on the synthesis
of TGF-b (Figure 8c).
BMP-7 upregulated PPAR-c expression
Incubation of HMCs with pIgA from patients or controls
did not alter gene expression of peroxisome proliferator-
activated receptor-g (PPAR-g). However, gene expression of
PPAR-g increased significantly (Po0.001) when BMP-7
(250 ng/ml) was added (Figure 9a). BMP-7 increased the
expression of PPAR-g at both transcriptional and post-
transcriptional levels in a dose-dependent manner (Figure 9b
and c).
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Figure 2 | Detection of BMP-7 receptors in cultured HMCs. (a) Constitutive gene expression of the five BMP receptors, including ALK2,
ALK3, ALK6, ActRII, and BMPR-II, in cultured HMCs by reverse transcription-PCR. (b) Representative immunochemical staining of receptors
for BMP-7 in cultured HMCs. (c) Expression of receptors for BMP-7 in HMCs cultured with pIgA preparations as determined by flow
cytometry. There is significant decrease in the expression of ALK-2, ALK-6, and BMPR-II in HMCs cultured with pIgA from IgAN patients as
compared with that of the control. The results represent mean±s.d. of 32 patients and 32 healthy controls.
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Effect of rosiglitazone on cytokine release and NF-jB
activation induced by TNF-a or pIgA
HMCs were cultured with pIgA or TNF-a in the presence or
absence of PPAR-g agonist (rosiglitazone). Rosiglitazone
significantly reduced TNF-a and IL-6 release by HMCs
induced by TNF-a (Figure 10a) or pIgA from IgAN patients
(Figure 10b). PIgA, but not TNF-a, increased TGF-b
release by HMCs (Figure 10a and b). This upregulation of
TGF-b release by pIgA was not affected by rosiglitazone
(Figure 10b).
Effect of rosiglitazone or BMP-7 on NF-jB activation induced
by TNF-a or pIgA
The role nuclear factor-kB (NF-kB) in the induction of
QJ;TNF-a and IL-6 by HMCs cultured with TNF-a or pIgA
was examined by electrophoretic mobility-shift assay (EMSA)
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Figure 3 | Assay for metabolic activity, cell viability and proliferation, and apoptosis. (a) WST conversion by HMCs cultured with
different IgA preparations with or without BMP-7 (250 ng/ml). PIgA from patients with IgAN significantly increases the metabolic activity
when compared with that of control subjects. The enhanced metabolic activity in HMCs induced by pIgA from IgAN patients is reduced by
BMP-7. Results are expressed as percentage changes in absorbance relative to that of the medium control (HMCs incubated with plain
medium alone). (b) LDH release from HMCs cultured with pIgA preparations. No cytotoxicity is detected in cells incubated with different
pIgA preparations in the presence or absence of BMP-7. Results are expressed as percentage changes in relative LDH release (absorbance
ratio between the LDH release and the total intracellular LDH) compared with that of the medium control. (c) PIgA from patients with IgAN
significantly increases the cell proliferation in HMCs determined by the bromodeoxyuridine incorporation assay. The cell proliferation
induced by pIgA from IgAN patients is reduced by BMP-7. (d) Caspase-3 assay showing no increased apoptosis in HMCs cultured with
different IgA preparations. Ultraviolet irradiated HMCs serve as positive control. (e) PIgA from patients with IgAN significantly increases HMC
proliferation as determined by the cell count. The increased cell count by cultured HMCs with pIgA from IgAN patients is attenuated by
BMP-7. (f) Flow cytometric TdT-mediated X-dUTP nick-end labeling assay further demonstrates that no increased apoptosis in HMC cultured
with different IgA preparations. HMCs treated 48 h with 0.5mM doxorubicin (Dox.) were used as positive control. All results from (a–d)
represent mean±s.d. of 32 patients and 32 healthy controls. Data from panels e and f are expressed as means±s.d. of five patients or five
healthy controls. *Po0.001 versus medium control; #Po0.001 versus HMCs cultured with pIgA preparation from controls; @Po0.001 versus
HMCs cultured with pIgA preparation from patients in the presence of BMP-7; OPo0.05 versus medium control; @Po0.001 versus HMC
cultured with pIgA for same duration in the presence of BMP-7.
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and immunofluorescence staining. As depicted in Figure 10c
and d, translocation of NF-kB into the nucleus of HMCs
occurred after exposure to pIgA or TNF-a. Furthermore,
both BMP-7 and rosiglitazone attenuated nuclear transloca-
tion of NF-kB activated by pIgA or TNF-a.
BMP-7 increased Smad6 and Smad7 expression in HMCs
There was no change in gene expression of Smad6
(Figure 11a) or Smad7 (Figure 11b) when HMCs were
incubated with pIgA from patients or controls. However,
addition of BMP-7 (250 ng/ml) significantly increased gene
expression of Smad6 and Smad7 (Po0.001). BMP-7 at
concentrations 4125 ng/ml increased the expression of
Smad6 (Figure 11c) and Smad7 (Figure 11d) in HMCs in a
dose-dependent manner (Po0.01). Activation of Smad2/3
and expression of Smad6 and Smad7 protein was also
examined by western blotting (Figure 11e). Upregulation
of phosphorylated Smad2/3 (pSmad2/3) was induced by
pIgA but not TNF-a. The pIgA-induced activation of Smad2/3
was blunted by BMP-7. There was no induction of Smad6 or
Smad7 protein when HMCs were incubated with pIgA or
TNF-a alone without BMP-7. The addition of BMP-7
induced protein synthesis of Smad6 and Smad7 by HMCs
preincubated with pIgA or TNF-a.
DISCUSSION
BMP-7 is the most abundant BMP in fetal and adult
mammalian kidney.5 Cortical and medullary BMP-7 mRNA
expression decreased markedly in rats with ischemia–reperfu-
sion injury. Intravenous administration of recombinant
BMP-7 reduces histological and functional injuries in a rat
model of ischemic acute renal failure.9 In murine model of
unilateral ureteral obstruction, BMP-7 effectively prevented
interstitial inflammation and tubulointerstitial fibrosis, leading
to preservation of renal function.8 In addition, BMP-7
treatment significantly reduced interstitial macrophage infil-
tration, raising the possibility of regulation of chemokine
expression in renal cells by BMP-7. In murine streptozocin-
induced diabetic nephropathy, tubular BMP-7 expression was
reduced and the reduction was associated with transdiffer-
entiation of tubular cells.10 Exogenous BMP-7 therapy partially
reversed renal hypertrophy and restored glomerular filtration
rate in a dose-dependent manner.14 In MRL lpr/lpr murine
lupus nephritis, BMP-7 administration for 10 weeks reduced
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Figure 4 | Gene expression and protein synthesis of TNF-a in HMCs cultured with different pIgA preparations with or without
BMP-7. (a) The gene expression and (b) protein synthesis of TNF-a increase in HMCs cultured with pIgA from patients with IgAN
(0.5 mg/ml). BMP-7 (250 ng/ml) reduces gene expression and protein synthesis of TNF-a induced by pIgA from IgAN patients. All results
represent mean±s.d. of 32 patients and 32 healthy controls. *Po0.001 versus medium control; #Po0.001 versus HMCs cultured with
pIgA preparation from controls; @Po0.001 versus HMCs cultured with pIgA preparation from patients in the presence of BMP-7.
(c) BMP-7 dose dependently decreases the protein synthesis of TNF-a induced by pIgA from IgAN patients. YPo0.01 or sPo0.05 versus
HMCs cultured with pIgA in the absence of BMP-7. Data are expressed as means±s.d. of five separate experiments.
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glomerular abnormality and tubulointerstitial fibrosis.11
Nonetheless, research on BMP-7 in IgAN is not available.
BMP-7 circulates in the blood at a concentration range of
100 to 300 pg/ml.15 The optimal therapeutic dose of BMP-7
used in various animal models of chronic kidney disease is
about 300 mg/kg.16 Despite the absence of sufficiently high
levels of BMP-7 in the circulating blood to stimulate cells,
HMC has BMP-7 receptors and is responsive to BMP-7.17
The concentration of BMP-7 used in this study is 250 ng/ml
and is comparable to the dose that was reported in various in
vitro models.11,18 It is speculated that mesangial damage by
the pathogenic pIgA molecules could be ameliorated if
specific delivery of this amount of exogenous BMP-7 into the
glomerulus or mesangium in vivo.
The present data confirmed our previous finding that
pIgA from patients with IgAN increased HMC proliferation
with upregulatory synthesis of TNF-a, TGF-b, and IL-6.3,4,19
We found that glomerular expression of BMP-7 was markedly
diminished in IgAN. Furthermore, expression of ALK2,
ALK6, and BMPR-II was significantly reduced in HMCs
cultured with pIgA from IgAN patients. In vitro studies
showed BMP-7 significantly reduced pIgA-induced HMC
proliferation, fibronectin synthesis, and immune injury.
These in vivo and in vitro data provide new evidences that
BMP-7 could counteract the actions of the profibrotic TGF-b
and proinflammatory TNF-a in IgAN, and hence ameliorat-
ing the pIgA-induced injury in mesangial cells. TNF-a is an
important mediator in the pathogenesis of IgAN. TNF-a is
produced early in the inflammatory process and induces the
expression of major histocompatibility complex class-I and
class-II molecules.20,21 Overexpression of TNF-a leads to
release of other mediators, upregulation of endothelial
adhesion molecules and other proinflammatory growth
factors, including IL-6, IL-8, and TNF-a itself.22 We showed
that BMP-7 not only reduced the upregulation of IL-6 and
TNF-a induced by pIgA, but, most interestingly, also blocked
the autocrine loops of amplification of immune injury to
mesangial cells initiated by TNF-a and TGF-b. These data
lend support to the notion that exogenous BMP-7 delivery to
the kidney is a promising therapeutic in IgAN, especially
BMP-7 is an endogenous molecule with minimal potential of
self-toxicity.
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Figure 5 | Gene expression and protein synthesis of IL-6 in HMCs cultured with different pIgA preparations with or without BMP-7.
Both gene expression (a) and protein synthesis (b) of IL-6 increase in HMCs cultured with pIgA from patients with IgAN or pIgA from
healthy controls (0.5 mg/ml). BMP-7 (250 ng/ml) reduces gene expression and protein synthesis of IL-6 induced by pIgA from IgAN patients.
All results represent mean±s.d. of 32 patients and 32 healthy controls. *Po0.001 versus medium control; OPo0.05 versus medium
control; #Po0.001 versus HMCs cultured with pIgA preparation from controls; fPo0.05 versus HMCs cultured with pIgA preparation
from controls in the presence of BMP-7; @Po0.001 versus HMCs cultured with pIgA preparation from patients in the presence of BMP-7.
(c). BMP-7 dose dependently decreases the protein synthesis of IL-6 induced by pIgA from IgAN patients. YPo0.01 or sPo0.05 versus HMCs
cultured with pIgA in the absence of BMP-7. Data are expressed as means±s.d. of five separate experiments.
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Figure 6 | Gene expression and protein synthesis of TGF-b in HMCs cultured with different pIgA preparations with or without
BMP-7. (a) The gene expression and (b) protein synthesis of TGF-b increase in HMCs cultured with pIgA from patients with IgAN
(0.5 mg/ml). BMP-7 (250 ng/ml) reduces gene expression and protein synthesis of TGF-b induced by pIgA from patients. All results represent
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Medium
control Control IgAN
BMP-7 – – –+ +
Medium
control Control IgAN
BMP-7 – – –+ +
Medium
control
Control IgAN
BMP-7 – – –+ +
Medium
control
Control IgAN
BMP-7 – – –+ +
Fibronectin
GAPDH
Fibronectin
Actin
* #@
*
* #@
1.5
1.2
0.9
0.6
0.3
0.0
Fi
br
on
ec
tin
 / 
G
AP
DH
 a
m
pl
ico
n 
ra
tio
700
800
600
500
400
300
200
100
0
Ω
Ar
bi
tra
ry
 u
ni
t
Figure 7 | Gene expression and protein synthesis of fibronectin in HMCs cultured with different pIgA preparations with or without
BMP-7. (a) The gene expression and (b) protein synthesis of fibronectin increase in HMCs cultured with pIgA from patients with IgAN
(0.5 mg/ml). BMP-7 (250 ng/ml) reduces the gene expression and protein synthesis of fibronectin induced by pIgA from patients. Gene
expression results represent mean±s.d. of 32 patients and 32 healthy controls. Immunoblot data represent mean±s.d. of 10 patients and
10 healthy controls. *Po0.001 versus medium control; OPo0.05 versus medium control; #Po0.001 versus HMCs cultured with pIgA
preparation from control; @Po0.001 versus HMCs cultured with pIgA preparation from patients in the presence of BMP-7.
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Although a reno-protective role of BMP-7 in acute and
chronic kidney diseases is increasingly convincing, the
mechanisms of these protective effects are not well defined.
In murine mesangial cell culture, BMP-7 antagonized the
fibrotic effect of TGF-b by suppressing the plasminogen
activator inhibitor-1 through maintaining the level of matrix
metalloprotease-2.12 In HMC culture, BMP-7 inhibited basal
and IL-1b-induced release of MCP-1 through activity of
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c-Jun N-terminal kinase and AP-1 activation.23 In this study,
we provided novel evidence that BMP-7 suppressed immune
injury in HMCs induced by pIgA through two distinct
signaling pathways, namely, the PPAR-g and inhibitory
Smads.
PPARs are a family of ligand-activated nuclear hormone
receptors that belong to the steroid-receptor superfamily.24
Recent studies suggest that antidiabetic thiazolidinediones,
acting as a PPAR-g agonist, possess anti-inflammatory
properties independent of their insulin-sensitizing action.25
PPAR-g agonists may exert their anti-inflammatory effects by
negatively regulating the expression of proinflammatory
genes (transcriptional transrepression) through inhibition
of transcriptional factors such as NF-kB.26 Rosiglitazone
(a thiazolidinediones) reduces the serum level of TNF-a and
IL-1b during sepsis in a murine sepsis model.27 PPAR-g
agonists also abrogate ischemia–reperfusion kidney injury28
and proliferative mesangial diseases,29 and block mesangial
expansion in diabetic glomerulosclerosis.30 The observed
anti-inflammatory effect of rosiglitazone in proximal tubular
epithelial cells is suggested to be due to inhibition of NF-kB
activation.27 We demonstrated that BMP-7 increased PPAR-g
expression by HMCs cultured with pIgA. The enhanced
release of TNF-a in HMCs induced by pIgA or exogenous
TNF-a was reduced by the PPAR-g agonist, rosiglitazone.
Both BMP-7 and rosiglitazone attenuated nuclear transloca-
tion of NF-kB activated by pIgA or TNF-a. These observa-
tions suggest the anti-inflammatory effect of BMP-7 to be
associated with PPAR-g activation.
In contrast to TNF-a, we found that upregulation of TGF-b
induced by pIgA was independent of PPAR-g activation and
was not attenuated by rosiglitazone. Previously, we reported
that pIgA upregulated TGF-b synthesis in cultured HMCs
associated with increased Smad activities (Smad2 and
Smad3).3 BMP-7 and TGF-b belong to the same family of
pleiotropic cytokines. The action of TGF-b is mediated
through pathway analogous to that of BMP-7.31 Smads
function as intracellular signaling mediators and regulators of
BMP-7 and TGF-b. Cross talk between the BMP-7 and TGF-
b pathway through inhibitory Smad protein exists in various
systems. In vascular smooth muscle, BMP-7 is able to reverse
the effect of TGF-b through activation of the inhibitory
Smad7.32 It has been suggested that Smad6 is involved in the
antagonism of TGF-b response by BMP-7 in mouse
mesangial cells.33 In tubular cell line HK-2, BMP-7
significantly increased mRNA expression of Smad6 and
Smad7.34 It is, therefore, logical to hypothesize that BMP-7
could also suppress Smad protein activation through similar
mechanism.
TGF-b is produced through translation and subsequent
cleavage of a latent dimeric precursor. Expression of TGF-b is
regulated through autocrine feedback mechanism.35,36 A
TRE-like sequence proximal to the major transcription site of
TGF-b promotor is implicated in auto-induction of TGF-b
expression.37 The observations of the absence of TGF-b auto-
induction in Smad3-negative cell lines38 and the inhibition by
dominant-negative Smad3 strongly suggest that Smad3 is
pivotal in the auto-induction process.39 Smad7 interferes
with TGF-b signaling through inhibition of the phosphor-
ylation of Smad2/3 and subsequent translocation to
nucleus.40,41 Our present finding of Smad7 upregulation in
HMCs induced by BMP-7 raises the possibility that BMP-7
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interrupts the autocrine feedback of TGF-b expression
through suppression of regulatory-Smads phosphorylation.
However, upregulation of Smad7 by BMP-7 cannot ade-
quately explain our finding of BMP-7 downregulating TGF-b
expression induced by pIgA. Whereas Smad7 acts as a general
signaling inhibitor of the TGF-b family, Smad6 preferentially
inhibits signaling of BMP.40,42 We have demonstrated that
pIgA from IgAN patients upregulates TGF-b production
by HMCs via increased angiotensin-II.43 Angiotensin-II
increases synthesis of aldosterone and is responsible for cardiac
and renal injury.44 Rats receiving aldosterone infusion exhibit
increased renal cortical mRNA levels of TGF-b and pSmad2/3.45
Aldosterone also stimulates increased mesangial cell
in vitro.46 The mineralocorticoid receptor (MR), expressed
constitutively in the glomerulus, is involved in renal
inflammation, tissue remodeling, and fibrosis.47 Dual block-
ade of aldosterone and angiotensin-II synergistically sup-
presses TGF-b expression in the hypertensive kidney.48
Medium
control Control IgAN
BMP-7 – – –+ +
Medium
control Control IgAN
Medium
control Control IgAN TNF-α
BMP-7 – – –+ +
Medium
control
Control IgAN
BMP-7 – – –+ +
Medium
control
Control IgAN
BMP-7 – – –+ +
Smad6
GAPDH
Smad7
Smad7
GAPDH
*
Θ *Θ
* #
* #
0.8
0.6
0.4
0.2
0.0Sm
ad
6 
/ G
AP
DH
 a
m
pl
ico
n 
ra
tio
0.8
0.6
0.4
0.2
0.0Sm
ad
6 
/ G
AP
DH
 a
m
pl
ico
n 
ra
tio
Sm
ad
7 
/ G
AP
DH
 a
m
pl
ico
n 
ra
tio
Sm
ad
7 
/ G
AP
DH
 a
m
pl
ico
n 
ra
tio
*
1.5
1.2
0.9
0.6
0.3
0.0
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Ω
GAPDH
Smad6
GAPDH
ng/ml BMP-7
BMP-7 (ng/ml)
BMP-7
Ω
Ω
*
Ω
*
*
*
0 62.5 125 250 500 1000ng/ml BMP-70 62.5 125 250 500 1000
0 62.5 125 250 500 1000
BMP-7 (ng/ml)
0 62.5 125 250 500 1000
p-Smad2/3
Smad2/3
Smad6
Smad7
Actin
– – + – + – +
Figure 11 | Effect of BMP-7 on Smad6 and Smad7 expression in HMCs. (a) PIgA from patients with IgAN or healthy control do not
increase gene expression of Smad6 in HMCs. (b) PIgA from patients with IgAN, but not pIgA from healthy control, increases gene expression
of Smad7 in HMCs. Addition of BMP-7 (250 ng/ml) further increases gene expression of Smad6 and Smad7 in HMCs. Results represent
mean±s.d. of 32 patients and 32 healthy controls. *Po0.001 versus medium control without pIgA or BMP-7; #Po0.001 versus HMCs
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BMP-7 upregulates gene expression of (c) Smad6 and (d) Smad7 in HMCs in a dose-dependent manner. *Po0.001 versus medium control;
OPo0.05 versus medium control. Data are obtained from five separate experiments. (e) Representative immunoblot demonstrating
upregulation of pSmad2/3 by pIgA but not by TNF-a. The activation of Smad2/3 induced by pIgA is blunted by BMP-7. BMP-7 upregulates
Smad6 and Smad7 proteins, whereas pIgA from IgAN patients only upregulates Smad7. Data are obtained from five separate experiments.
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Smad6, but not Smad7, suppresses transcriptional activity of
glucocorticoid and mineralocorticoid receptors (MR) via its
C-terminal MH2 Domain by attracting histones deacetylase,
histones deacetylase-3, and antagonizing the acetylation of
histone induced by p160-type histone acetyltransferase
coactivators.49 Taken these observations together with our
in vitro data, we postulate that suppression of TGF-b release
in HMCs by BMP-7 resulted from a cross talk between the
BMP-7 and TGF-b pathway through the common inhibitory
Smad6 and Smad7. Figure 12 outlines a schema of the
possible protective role of BMP-7 in IgAN. Smad6 induced by
BMP-7 suppresses the transcriptional activity of MR and the
subsequent expression of TGF-b. Meanwhile, Smad7 induced
by BMP-7 interferes the autocrine feedback loop of TGF-b
production. However, further investigation is warranted to
confirm this hypothesis.
In summary, we have demonstrated that glomerular BMP
expression is significantly reduced in IgAN. BMP-7 di-
minishes TNF-a, IL-6, and TGF-b release in cultured HMCs
induced by pIgA, through different regulatory mechanisms.
BMP-7 inhibits TNF-a release in HMCs stimulated by pIgA,
via activation of PPAR-g. The suppression of TGF-b release
in HMCs by BMP-7 results from a cross talk between the
BMP-7 and TGF-b pathway through the I-Smads.
MATERIALS AND METHODS
Materials
Jacalin agarose was purchased from Pierce (Rockford, IL, USA).
Rosewell Park Memorial Institute Medium (RPMI-1640 medium)
and fetal bovine serum were obtained from Life Technologies
(Rockville, MD, USA). Antibodies to BMP receptors, recombinant
TNF-a, and BMP-7 were obtained from R&D Systems (Minneapolis,
MN, USA). Secondary antibodies and isotypic control antibodies for
immunochemical staining and flow cytometry were obtained from
Dako (Kyoto, Japan). Rosiglitazone was a gift from GlaxoSmithKline
(Middlesex, UK). All other chemicals were from Sigma (St Louis,
MO, USA).
Patients and controls
The study was conducted in accordance with the Declaration of
Helsinki Principles and was approved by the institutional ethics
committee for studies in human. Thirty-two Chinese patients (18
male and 14 female) with clinical and renal immunopathological
diagnosis of primary IgAN were included. All the patients were
symptomatic for more than 12 months, with no significant renal
impairment. Systemic lupus erythematosus, Henoch–Schonlein
purpura, and hepatic diseases were excluded by clinical history,
examination, and negative laboratory findings for hypocomplemen-
temia, anti-DNA antibody, or hepatitis B virus surface antigen.
Thirty-two subjects (18 male and 14 female), comparable in age and
race, with no microscopic hematuria or proteinuria, were recruited
as normal controls.
Immunofluorescence examination
Renal tissues were obtained from 15 normotensive patients with
mild IgAN (grade 1) admitted consecutively for diagnostic renal
biopsy for investigation of microscopic hematuria. They had not
previously received angiotensin-converting enzyme inhibitor or
angiotensin II receptor type 1 antagonist. Control renal tissues were
obtained from the intact pole of kidneys removed from eight
normotensive subjects (comparable in age, sex, and race) with single
circumscribed tumor. The glomerular expression of BMP-7 or
nephrin was detected by immunofluorescence staining using Alexa
Fluor-488- or Alexa Fluor-594-conjugated secondary antibodies
(Invitrogen, Carlsbad, CA, USA). Cell nuclei were counterstained
with 40,60-diamidino-2-phenylindole hydrochloride. Two renal
pathologists without prior knowledge of clinical or laboratory data
evaluated the expression BMP-7 staining using an arbitrary 0–5þ
scale. All glomeruli were examined at an original magnification of
 400. The preset grading criteria for glomerular BMP-7 staining
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Figure 12 | Schema showing the possible protective role of BMP-7 in IgAN. The synthesis of TNF-a, IL-6, and TGF-b is increased in HMC
exposed to pathogenic IgA from patients with IgAN. BMP-7 activates the nuclear receptor PPAR-g and represses the expression and release
of TNF-a. PIgA activate HMCs to release angiotensin-II and increase the synthesis of aldosterone. Aldosterone induces TGF-b synthesis
through the activation of MR. The activated MR translocates to the nucleus and binds to the glucocorticoid-responsive element (GRE) and
hence initiates transcription of TGF-b. Smad6 induced by BMP-7 downregulates the TGF-b synthesis by silencing the transcriptional activity
of MR through recruitment of histone deacetylase 3. Smad7 induced by BMP-7 further suppresses autocrine amplification of TGF-b synthesis
by inhibiting phosphorylation of Smad2/3.
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were as follows: zero if no glomerular staining, 1þ if o10% was
positive; 2þ if 10 to o20% was positive; 3þ if 20 to o40% was
positive; 4þ if 40 to o60% was positive; and 5þ if 60% or more
was positive.43
Immunohistochemical staining
Isolation, characterization, and culture of HMCs were performed as
previously described.50 HMCs were grown on eight-well chamber
slides (Nalge Nunc International, Naperville, IL, USA). Immuno-
chemical staining of BMP receptors was performed by incubating
cells with primary antibodies (10-fold diluted) for 30 min, followed
by 30 min of incubation with the corresponding horseradish
peroxidase-conjugated secondary antibody.
Purification of pIgA
Total IgA1 were isolated from the sera of patients or controls using
Jacalin affinity chromatography followed by size-exclusion chroma-
tography with a Fast Protein Liquid Chromatography System
(Uppsala, Sweden). IgA fractions (confirmed by SDS–polyacryla-
mide gel electrophoresis and ELISA) with molecular weight
4320 kDa were pooled as pIgA.50 The endotoxin content in the
IgA preparations was o1 pg/mg protein as determined by Limulus
amoebocyte lysate assay (BioWhittaker, Walkersville, MD, USA).
Flow cytometry
HMCs were grown to log phase and cultured for 24 h with pIgA
preparations. The cell concentration was adjusted to 5 106/ml and
200ml of cell suspension were incubated with antibodies to BMP
receptors for 30 min at 4 1C. After incubation and washing, the cells
were then incubated with 100ml of fluorescein-conjugated secondary
antibodies. The result was expressed as mean fluorescence
intensity.
Quantification of metabolic activity, cell proliferation, viabi-
lity, and apoptosis of HMCs cultured with pIgA preparations
The metabolic activity of HMCs was measured with a colorimetric
kit (Chemicon International, Temecula, CA, USA) based on cleavage
of the WST-1 (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-
phenyl)-2H-tetrazolium, monosodium salt). Results were expressed
as percentage changes in absorbance compared with that of the
medium control (defined as HMCs incubated with plain culture
medium). The cytotoxic effect of pIgA preparations on HMCs was
measured by lactate dehydrogenase (LDH) assay kit (Roche
Diagnostic, Indianapolis, IN, USA). The results were expressed as
percentage changes in LDH release (absorbance ratio between LDH
release and the total intracellular LDH) relative to that of the
medium control. HMC proliferation was measured using a
bromodeoxyuridine incorporation assay kit (Boehringer Mannheim
GmbH, Mannheim, Germany) and by direct cell counting. Results of
bromodeoxyuridine incorporation were expressed as percentage
changes in absorbance compared with that of the medium control.
Caspase-3 activity assay (Roche Diagnostics) or the TdT-mediated
X-dUTP nick-end labeling assay kit (Boehringer Mannheim) was
used to examine whether pIgA induces apoptosis in HMCs cultured
with pIgA.
Treatment of HMCs with pIgA preparations, BMP-7, or TNF-a
HMCs were subcultured onto six-well culture plates and were
growth-arrested for 24 h in RPMI-1640 medium with 0.5% fetal
calf serum before exposure to pIgA or TNF-a at increasing
Table 1 | Primer sequences for RT-PCR
Gene Primer Accession number
GAPDH Forward 50-ACCACAGTCCATGCCATCAC-30 AF261085
Reverse 50-TCCACCACCCTGTTGCTGTA-3
TNF-a Forward 50-GAGTGACAAGCCTGTAGCCCATGTTGTAGC-30 BC028148
Reverse 50-GCAATGATCCCAAAGTAGACCTGCCCAGAC-3
TGF-b Forward 50-AACCGGCTGCTGACCCCCACTG-30 M38449
Reverse 50-CGGGTT GTGTTGGTTGTAGAGG-3
IL-6 Forward 50-ATGAACTCCTTCACAAG-30 NM_000600
Reverse 50-TGTCAATTCGTTCTGAAGAG-30
PPAR-g Forward 50-AGACAACAGACAAATCACCAT-30 BT007281
Reverse 50-CAATGGGCTTCACATTCAGCA-30
Smad6 Forward 50-CCCCCGGCTACTCCATCAAGGTGT-30 NM_05585
Reverse 50-GTCCGTGGGGGCTGTGTCTCTGG-30
Smad7 Forward 50-ACTAACCCTCTCTGCCAATGT-30 AF026559
Reverse 50-GTTGTCCGAATTGAGCTGTCC-30
BMPR-II Forward 50-CTGCACAGTGTGCTGAGGAAAG-30 Z48923
Reverse 50-TGAACTGCCCTGTTACTGCCA-30
ActR-II Forward 50-GCAAAATGAATACGAAGTCTA-30 X62381
Reverse 50-GCAAAATCTAATACCTCTGGA-30
ActR-IIB Forward 50-ACACGGGAGTGCATCTACTACAACG-30 NM001106
Reverse 50-TTCATGAGCTGGGCCTTCCAGACAA-30
ALK2 Forward 50-ATGTCTTTTAGCCTGCCTGCTG-30 Z22534
Reverse 50-ATCAAGCTGATTGGTGCTCTGG-30
ALK3 Forward 50-TGATTTGGAACAGGATGAAGC-30 Z22535
Reverse 50-TGTAGCACATTTCAGGAAGTC-30
ALK6 Forward 50-GCAGCACAGACGGATATTGT-30 U89326
Reverse 50-TTTCATGCCTCATCAACACT-30
Fibronectin Forward 50-AGCCGCCACGTGCCAGGATTAC-30 XM_030544
Reverse 50-CTTATGGGGGTGGCCGTTGTG G-30
ActR, activin receptor; ALK, activin receptor-like kinase; BMPR, bone morphogenetic protein receptor; GAPDH, glyceraldehyde-3-phosphate-dehydrogenase; IL-6, interleukin-6;
PPAR-g, peroxisome proliferator-activated receptor-g; RT-PCR, reverse transcription-PCR; TGF-b, transforming growth factor-b; TNF-a, tumor necrosis factor-a.
Kidney International (2008) 74, 1026–1039 1037
WL Chan et al.: Role of BMP-7 in IgAN o r i g i n a l a r t i c l e
concentrations (0.5 mg/ml for pIgA and 0.01, 0.1, 1, and 10 ng/ml
for TNF-a) with or without preincubation of BMP-7 (250 ng/ml) or
rosiglitazone (0.5 mg/ml) 1 h before addition of pIgA or TNF-a. The
concentration of pIgA used was based on our previous data on
activation of mesangial TGF-b release.3 Cells were harvested for
RNA extraction after incubation for 6 h at 37 1C. Culture super-
natants were collected after 24 h of incubation for determination of
TNF-a, IL-6, and TGF-b levels by ELISA. The cell lysate was
prepared from HMCs after incubation for 48 h for analysis of
fibronectin, or for 1 h for analysis of PPAR-g, pSmad2/3, Smad6,
and Smad7 by western blotting. Cells were harvested after 30 min for
preparation of nuclear extracts for EMSA to detect NF-kB
translocation.
Total RNA extraction and reverse transcription-PCR
Total cellular RNA was extracted using a NucleoSpin RNA II
total RNA extraction kit (Macherey-Nagel, Duren, Germany).
Four micrograms of total RNA were reverse transcribed to
cDNA. The gene expression of BMPR-II, ActRII, ActRIIB,
ALK2, ALK3, ALK6, TNF-a, TGF-b, IL-6, fibronectin, PPAR-g,
Smad6, Smad7, and glyceraldehyde-3-phosphate-dehydrogenase by
HMCs was examined by PCR using specific primers designed from
known sequences in the GenBank (Table 1). PCR results were
expressed as the ratio of the target amplicon to glyceraldehyde-3-
phosphate-dehydrogenase amplicon. Full precaution was taken for
all necessary steps to ensure validity of the result as previously
described.51
ELISA of TNF-a, IL-6, and TGF-b in culture supernatants
Human TNF-a, TGF-b, and IL-6 levels were measured with ELISA
kits (Bender MedSystems, Vienna, Austria). The detection sensitivity
for TNF-a, TGF-b, and IL-6 was 5, 10, and 1.6 pg/ml, while the
intra-batch coefficient of variation was ±7.8, 4.6, and 6.3%,
respectively.
Western blot analysis
Cell extracts were pelleted at 15,000 g. Ten micrograms of total
protein extract from 106 cells were electrophoresed and transferred
to polyvinylidene difluoride membranes. The membrane was
probed with anti-PPAR-g, anti-pSmad2/3, anti-Smad6, anti-Smad7,
or anti-fibronectin (all at 10 mg/ml) in phosphate-buffered sali-
ne–Tween for 16 h at 4 1C. The membrane was incubated with a
peroxidase-labeled secondary antibodies and the antigen–antibody
reaction was detected with ECL plus chemiluminescence (Amer-
sham Pharmacia Biotech, Arlington, IL, USA).
Electrophoretic mobility-shift assay
Standard EMSA was performed for detection of NF-kB. HMCs were
treated for 1 h with pIgA or TNF-a. The nuclear extract was
prepared using the NE-PER nuclear extraction reagent (Pierce). The
oligonucleotide (AGTTGAGGGGACTTTCCCAGGC; the core
sequence is in italics) for NF-kB was biotinylated using the Biotin 30
end labeling kit (Pierce), and EMSA was performed with the
LightShift chemiluminescent EMSA kit (Pierce). Parallel experi-
ments with preincubation of BMP-7 or rosiglitazone in addition to
pIgA or TNF-a were performed to determine whether BMP-7 or
PPAR-g agonist might exert its anti-inflammatory effect through
NF-kB inhibition. Visualization of nuclear translocation of NF-kB
was detected by immunofluorescence staining using anti-NF-kB
p65-specific antibody.
Statistical analyses
All data (cell culture experiments) were expressed as means±s.d.
Inter-group differences for continuous variables were assessed by the
unpaired t-test. The protein synthesis in HMCs following exposure
to different concentrations of IgA preparations was analyzed with
multivariate analysis of variance followed by Bonferroni’s method to
control for multiple testing. All P-values quoted are two-tailed and
significance is defined as Po0.05.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
The study was supported by the Research Grant Committee (Hong
Kong) (HKU 7546/05M) and Dr LY Chan was partly supported by
L & T Charitable Foundation and the House of INDOCAFE.
REFERENCES
1. D’Amico G. The commonest glomerulonephritis in the world: IgA
nephropathy. Q J Med 1987; 64: 709–727.
2. Julian BA, Tomana M, Novak J et al. Progress in the pathogenesis of IgA
nephropathy. Adv Nephrol Necker Hosp 1999; 29: 53–72.
3. Lai KN, Tang SC, Guh JY et al. Polymeric IgA1 from patients with IgA
nephropathy upregulates transforming growth factor-beta synthesis and
signal transduction in human mesangial cells via the rennin–angiotensin
system. J Am Soc Nephrol 2003; 14: 3127–3137.
4. Leung JC, Tang SC, Chan LY et al. Polymeric IgA increases the synthesis
of macrophage migration inhibitory factor by human mesangial cells in
IgA nephropathy. Nephrol Dial Transplant 2003; 18: 36–45.
5. Helder MN, Ozkaynak E, Sampath KT et al. Expression pattern of
osteogenic protein-1 (bone morphogenetic protein-7) in human and
mouse development. J Histochem Cytochem 1995; 43: 1035–1044.
6. Kopp JB. BMP receptors in kidney. Kidney Int 2000; 58: 2237–2238.
7. Ebara S, Nakayama K. Mechanism for the action of bone morphogenetic
proteins and regulation of their activity. Spine 2002; 27: S10–S15.
8. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis: the role
of bone morphogenic protein-7 and hepatocyte growth factor. Kidney Int
Suppl 2003; 64: S105–S112.
9. Vukicevic S, Basic V, Rogic D et al. Osteogenic protein-1 (bone
morphogenetic protein-7) reduces severity of injury after ischemic acute
renal failure in rat. J Clin Invest 1998; 102: 202–214.
10. Wang SN, Lapage J, Hirschberg R. Loss of tubular bone morphogenetic
protein-7 in diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2392–2399.
11. Zeisberg M, Bottiglio C, Kumar N et al. Bone morphogenic protein-7
inhibits progression of chronic renal fibrosis associated with two genetic
mouse models. Am J Physiol Renal Physiol 2003; 285: F1060–F1067.
12. Wang S, Hirschberg R. BMP7 antagonizes TGF-beta -dependent
fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 2003; 284:
F1006–F1013.
13. Gould SE, Day M, Jones SS et al. BMP-7 regulates chemokine, cytokine,
and hemodynamic gene expression in proximal tubule cells. Kidney Int
2002; 61: 51–60.
14. Wang S, Chen Q, Simon TC et al. Bone morphogenic protein-7 (BMP-7), a
novel therapy for diabetic nephropathy. Kidney Int 2003; 63: 2037–2049.
15. Vukicevic S, Latin V, Chen P et al. Localization of osteogenic protein-1
(bone morphogenetic protein-7) during human embryonic development:
high affinity binding to basement membranes. Biochem Biophys Res
Commun 1994; 198: 693–700.
16. Zeisberg M. Bone morphogenic protein-7 and the kidney: current
concepts and open questions. Nephrol Dial Transplant 2006; 21: 568–573.
17. Miyazaki Y, Ueda H, Yokoo T et al. Inhibition of endogenous BMP in the
glomerulus leads to mesangial matrix expansion. Biochem Biophys Res
Commun 2006; 340: 681–688.
18. Sugimoto H, Grahovac G, Zeisberg M et al. Renal fibrosis and
glomerulosclerosis in a new mouse model of diabetic nephropathy and
its regression by bone morphogenic protein-7 and advanced glycation
end product inhibitors. Diabetes 2007; 56: 1825–1833.
19. Chan LY, Leung JC, Tsang AW et al. Activation of tubular epithelial cells
by mesangial-derived TNF-alpha: glomerulotubular communication in
IgA nephropathy. Kidney Int 2005; 67: 602–612.
20. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev
Immunol 1992; 10: 411–452.
1038 Kidney International (2008) 74, 1026–1039
o r i g i n a l a r t i c l e WL Chan et al.: Role of BMP-7 in IgAN
21. Feldmann M, Brennan FM, Maini R. Cytokines in autoimmune disorders.
Int Rev Immunol 1998; 17: 217–228.
22. Ruddle NH. Tumor necrosis factor (TNF-alpha) and lymphotoxin
(TNF-beta). Curr Opin Immunol 1992; 4: 327–332.
23. Lee MJ, Yang CW, Jin DC et al. Bone morphogenetic protein-7 inhibits
constitutive and interleukin-1 beta-induced monocyte chemoattractant
protein-1 expression in human mesangial cells: role for JNK/AP-1
pathway. J Immunol 2003; 170: 2557–2563.
24. Evans RM. The steroid and thyroid hormone receptor superfamily. Science
1988; 240: 889–895.
25. Lebovitz HE, Dole JF, Patwardhan R et al. Rosiglitazone monotherapy is
effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;
86: 280–288.
26. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha
activation modulates cellular redox status, represses nuclear factor-
kappaB signaling, and reduces inflammatory cytokine production in
aging. J Biol Chem 1998; 273: 32833–32841.
27. Lee S, Kim W, Kang KP et al. Agonist of peroxisome proliferator-activated
receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a
murine sepsis model. Nephrol Dial Transplant 2005; 20: 1057–1065.
28. Sivarajah A, Chatterjee PK, Patel NS et al. Agonists of peroxisome-
proliferator activated receptor-gamma reduce renal ischemia/reperfusion
injury. Am J Nephrol 2003; 23: 267–276.
29. Ghosh SS, Gehr TW, Ghosh S et al. PPARgamma ligand attenuates
PDGF-induced mesangial cell proliferation: role of MAP kinase. Kidney Int
2003; 64: 52–62.
30. McCarthy KJ, Routh RE, Shaw W et al. Troglitazone halts diabetic
glomerulosclerosis by blockade of mesangial expansion. Kidney Int 2000;
58: 2341–2350.
31. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional
targets, regulation of signals, and signaling cross-talk. Cytokine Growth
Factor Rev 2005; 16: 251–263.
32. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular
calcification. Circ Res 2005; 97: 105–114.
33. Wang S, Hirschberg R. Bone morphogenetic protein-7 signals opposing
transforming growth factor beta in mesangial cells. J Biol Chem 2004;
279: 23200–23206.
34. Wetzel P, Haag J, Campean V et al. Bone morphogenetic protein-7
expression and activity in the human adult normal kidney is
predominantly localized to the distal nephron. Kidney Int 2006; 70:
717–723.
35. Ventura JJ, Kennedy NJ, Flavell RA et al. JNK regulates autocrine
expression of TGF-beta1. Mol Cell 2004; 15: 269–278.
36. Schrum LW, Bird MA, Salcher O et al. Autocrine expression of activated
transforming growth factor-beta(1) induces apoptosis in normal rat liver.
Am J Physiol Gastrointest Liver Physiol 2001; 280: G139–G148.
37. Kim SJ, Angel P, Lafyatis R et al. Autoinduction of transforming growth
factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 1990; 10:
1492–1497.
38. Wong C, Rougier-Chapman EM, Frederick JP et al. Smad3–Smad4 and
AP-1 complexes synergize in transcriptional activation of the c-Jun
promoter by transforming growth factor beta. Mol Cell Biol 1999; 19:
1821–1830.
39. Zhang M, Fraser D, Phillips A. ERK, p38, and Smad signaling pathways
differentially regulate transforming growth factor-beta1 autoinduction
in proximal tubular epithelial cells. Am J Pathol 2006; 169: 1282–1293.
40. Imamura T, Takase M, Nishihara A et al. Smad6 inhibits signalling by
the TGF-beta superfamily. Nature 1997; 389: 622–626.
41. Nakao A, Afrakhte M, Moren A et al. Identification of Smad7,
a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 1997;
389: 631–635.
42. Itoh F, Asao H, Sugamura K et al. Promoting bone morphogenetic
protein signaling through negative regulation of inhibitory Smads.
EMBO J 2001; 20: 4132–4142.
43. Chan LY, Leung JC, Tang SC et al. Tubular expression of angiotensin II
receptors and their regulation in IgA nephropathy. J Am Soc Nephrol
2005; 16: 2306–2317.
44. Hostetter TH, Rosenberg ME, Ibrahim HN et al. Aldosterone in progressive
renal disease. Semin Nephrol 2001; 21: 573–579.
45. Sun GP, Kohno M, Guo P et al. Involvements of Rho-kinase and TGF-beta
pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17:
2193–2201.
46. Terada Y, Kobayashi T, Kuwana H et al. Aldosterone stimulates
proliferation of mesangial cells by activating mitogen-activated
protein kinase 1/2, cyclin D1, and cyclin A. J Am Soc Nephrol 2005; 16:
2296–2305.
47. Quinkler M, Zehnder D, Eardley KS et al. Increased expression of
mineralocorticoid effector mechanisms in kidney biopsies of patients
with heavy proteinuria. Circulation 2005; 112: 1435–1443.
48. Onozato ML, Tojo A, Kobayashi N et al. Dual blockade of aldosterone
and angiotensin II additively suppresses TGF-beta and NADPH oxidase in
the hypertensive kidney. Nephrol Dial Transplant 2007; 22: 1314–1322.
49. Ichijo T, Voutetakis A, Cotrim AP et al. The Smad6-histone deacetylase 3
complex silences the transcriptional activity of the glucocorticoid
receptor: potential clinical implications. J Biol Chem 2005; 280:
42067–42077.
50. Leung JC, Tang SC, Lam MF et al. Charge-dependent binding of
polymeric IgA1 to human mesangial cells in IgA nephropathy. Kidney Int
2001; 59: 277–285.
51. Leung JC, Tsang AW, Chan DT et al. Absence of CD89, polymeric
immunoglobulin receptor, and asialoglycoprotein receptor on human
mesangial cells. J Am Soc Nephrol 2000; 11: 241–249.
Kidney International (2008) 74, 1026–1039 1039
WL Chan et al.: Role of BMP-7 in IgAN o r i g i n a l a r t i c l e
